The global AI in omics studies market size is expected to reach US$ 4,515.4 Mn by 2030, from US$ 639.8 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 32.2% during the forecast period.
Artificial intelligence (AI) is being leveraged across various fields of science to revolutionize research and discovery. In genomics and molecular research, AI is playing a pivotal role by assisting researchers in the analysis of large and complex omics datasets. There are various AI-based products that are used for omics data analysis.
One of the most commonly used products are gene expression analysis tools that use machine learning algorithms to identify patterns in transcriptomics data and deduce biological insights. These tools allow researchers to perform functional analysis, biomarker detection, and gene network modeling much more efficiently compared to traditional statistical methods. Other useful products include genomic and proteomic sequencing tools that employ deep learning for base calling, variant calling, and peptide identification from omics datasets. This has significantly boosted sequencing throughput and data accuracy.
While AI omics tools have clear advantages like speed, automation, and the ability to discover subtle patterns, there are still some challenges. The models used by these tools function as 'black-boxes' and do not provide explanations for their results. This can reduce the reliability and reproducibility of findings. Also, the performance of AI models depends on the quantity and quality of training data, limiting their usage for rare diseases. The standardization of datasets and models across platforms is another issue.
Global AI in Omics Studies Market- Regional Insights
Moreover, North America has a large pool of AI and data science experts who are working on collaborative projects between academia and industry. The region also has a receptive market environment and favorable regulations to support commercialization of AI-based diagnostic and research tools. Leading pharmaceutical and life sciences companies with significant research and development investments are using AI to accelerate drug discovery from omics data. These factors have made North America the dominant early adopter of AI-powered solutions and services for omics studies.
Figure 1. Global AI in Omics Studies Market Share (%), By Region, 2023
To learn more about this report, request sample copy
Analyst View: The AI in omics studies market is growing steadily and is expected to witness significant growth over the forecast period. The primary driver for the AI adoption in omics studies is its ability to analyze large and complex omics datasets. AI tools help researchers identify patterns, predictive biomarkers and gain novel biological insights from omics data more efficiently. North America dominated the market in 2021 due to heavy investments by pharmaceutical companies and presence of leading AI players in the region. Asia Pacific is projected to be the fastest-growing market during the forecast period owing to increasing R&D investments by China and India in omics and AI technologies.
However, the lack of skilled workforce to develop and deploy AI solutions remains a major restraint for wider adoption. Data integration and extracting meaningful insights from multi-omics datasets also pose challenges. Nevertheless, the growing partnership between AI and omics companies presents opportunities for the development of advanced analytics platforms. New startups are also offering cloud-based AI solutions to researchers, which is expanding the addressable market. The future outlook remains positive, with increasing acceptance of AI as an indispensable tool for accelerating omics research.
Global AI in Omics Studies Market- Drivers
As petabytes of genetic information pour in from these public efforts, there is an urgent need to analyze this deluge of complex data. This is driving significant investments in AI and machine learning to derive meaningful insights from omics datasets. Pharmaceutical companies and academic research centers are increasingly utilizing deep learning models to speed up drug discovery by better understanding genotype-phenotype correlations. Startups are also emerging that focus on developing AI tools tailored for precision medicine and disease prediction applications using genomic data.
AI techniques like machine learning and deep learning are being extensively used for applications such as gene sequencing, pharmacogenomics, biomarker development, and clinical decision support systems. For example, AI algorithms are analyzing genomic variations, RNA transcripts and protein expressions in a patient's biological sample to predict disease predisposition, diagnose conditions, track disease progression, and identify potential drug targets or therapies that may work best for that individual. Some AI systems can even monitor treatment responses and flag adverse events in near real-time by integrating omics profiles with electronic health records. This is allowing healthcare providers to deliver more effective precision care tailored to the unique biological characteristics of each patient.
The application of AI is also helping to automate many routine genomic workflows and tasks. Deep learning models have been developed to automatically interpret genomic variant calls with 99% accuracy, saving researchers immense time previously spent on manual validation and evaluation. Other AI tools can now automate complex processes like CRISPR genome editing design in a matter of hours versus months for human experts. As genomics studies generate petabytes of new data each year, automated systems powered by AI will be necessary to help analyze this deluge of information in a timely, cost-effective manner. This rise of AI-driven automation is reducing the workload on researchers, freeing them to focus on more innovative scientific questions.
Global AI in Omics Studies Market- Opportunities
For instance, AI is being used to sift through millions of chemical compounds to predict those most likely to effectively target proteins associated with a disease. This saves precious time compared to traditional trial and error methods. Pharmaceutical companies are also leveraging AI to improve strategies for repurposing existing drugs for new therapies. By revealing similarities between diseases or conditions at the molecular level, AI can uncover unexpected ways to deploy approved treatments for other illnesses.
As the COVID-19 pandemic showed, developing safe and effective vaccines typically takes years through conventional research. However, AI algorithms can now analyze coronavirus genomes sequenced from various geographic locations and predict how it may mutate over time. This helps vaccine designers stay ahead of new variants. Several AI tools are also expediting vaccine candidate screening and selection processes. For example, over 50 potential SARS-CoV-2 vaccine candidates were tested and two were selected for clinical trials just two months after the virus genomic sequence was disclosed, according to the World Health Organization (WHO)
Several factors make the emerging market conditions conducive to the wide adoption of AI tools in omics research. Firstly, in emerging nations, the population is often younger and has a greater prevalence of illness. This emphasizes the need for precision diagnostics and therapeutics. Secondly, governments are investing heavily in building biotech infrastructure to promote national priorities around bioprospecting and drug discovery. For instance, India's National Biopharma Mission aims to foster R&D collaborations between academia and industry. Thirdly, reducing the costs of genomic sequencing and data storage is making AI-driven multi-omics analysis feasible even for low-resource public health programs and hospitals in remote areas.
Global AI in Omics Studies Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 639.8 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 32.2% | 2030 Value Projection: | US$ 4,515.4 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Thermo Fisher Scientific, Agilent Technologies, Illumina, BGI Genomics, Dassault Systèmes, Qiagen, Waters Corporation, GE Healthcare, Amazon Web Services, Inc., Bruker, Danaher |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global AI in Omics Studies Market- Trends
As businesses embrace cloud-based tools and remote work enabled by technologies like cloud-hosted virtual meeting solutions, the demand for reliable and secure cloud infrastructure has also increased tremendously. To meet this demand, major cloud service providers like Amazon Web Services, Microsoft Azure and Google Cloud have been significantly expanding their data center presence globally. For example, Amazon Web ServicesCloud computing company,announced plans in late 2021 to invest US$5 billion in building 15 new data center regions worldwide by 2026. This rapid data center expansion allows cloud providers to reduce latency and better support customers across the world, attracting even more businesses to their platforms.
The growing adoption of cloud-based solutions by enterprises is creating a huge market opportunity for independent software vendors and cloud technology startups. More companies are developing cloud-native applications and workflows that are easy to deploy, manage and update in the cloud. This has driven strong investment and innovation in areas like serverless computing, containers, cloud storage, collaboration tools, cybersecurity, AI/ML, and more. The pandemic has accelerated this shift towards cloud-enabled digital transformation across all industries.
The integration of AI and IoT is also opening new opportunities through hyper-automation. Real-time data from connected devices can power automated decision making and workflows. Blockchain's ability to securely share data across organizational silos further enhances the potential of AI and IoT collaborations. When devices, systems, and trading partners can reliably transact, interact, and validate transactions in an automated manner, it drives efficiencies. For instance, blockchain and AI-powered smart contracts are streamlining supply chain processes for automakers like Ford by digitally tracking parts from suppliers. This is reducing paperwork and improving visibility into inventory levels.
Global AI in Omics Studies Market - Restraints
Several factors are contributing to the growing skills gap in cloud technologies. Traditional IT training programs are still catching up with the pace of innovation in the cloud domain. Cloud models require new skills around distributed systems, networking, serverless architecture, containerization, machine learning, etc. Re-skilling the existing workforce with these new age technologies is also a challenge. Many educational institutes have yet to design courses that can equip students with the relevant cloud skills. This is hampering the talent pipeline for cloud jobs.
At the same time, fast growing cloud players themselves are facing difficulties in recruiting sufficiently trained staff. According to a 2022 report by the World Economic Forum, over half of business leaders surveyed said they are facing significant talent shortfalls in areas like data science, cloud computing, and cybersecurity. This skills shortage acts as a constraint for companies to fully leverage cloud capabilities and scale their digital transformation. It reduces their agility and speed of innovation. Ultimately, it has a dampening effect on the pace at which organizations are willing to adopt cloud models and migrate their IT infrastructure and workloads to the cloud.
Moreover, in developing countries and remote areas, lack of access to high-speed internet continues to pose challenges. Reliable and speedy network connectivity is essential for businesses and individuals to fully leverage the advantages of cloud services. However, inadequate broadband penetration in parts of Africa and Asia is a hindrance. For example, according to the latest data from the International Telecommunication Union, approximately 31% of households in India still lack internet access as of 2021. The inability to ensure seamless data transfer poses difficulties for organizations in these regions to move their workloads and processes fully onto the cloud. Infrastructure deficits negatively impact user experience and undermine confidence in cloud solutions.
Figure 2. Global AI in Omics Studies Market Share (%), By Offering, 2023
To learn more about this report, request sample copy
Global AI in Omics Studies Market- Recent Developments
Product and Technology Launch
Acquisition and Collaboration
Top Companies in Global AI in Omics Studies Market
Definition: Artificial intelligence (AI) is a powerful approach for solving complex problems in the processing, analysis, and interpretation of omics data, as well as the integration of multi-omics and clinical data. In recent years, AI has enabled remarkable breakthroughs across diverse biomedical fields, such as genomic variant interpretation, protein structure prediction, disease diagnosis, and drug discovery.
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients